Skip to main content
x

Summit takes on Keytruda again

Summit will again pit its Akeso-originated anti-VEGF x PD-1 MAb ivonescimab against Merck & Co's Keytruda in lung cancer, a new clinicaltrials.gov listing has revealed. The phase 3 Harmoni-7 study will enrol PD-L1-high patients, and test OS and PFS as co-primary endpoints; the respective benchmarks for medians here are 26.3 months and 10.3 months in the Keynote-024 trial. Ivonescimab's chemo combo is already in the front-line NSCLC Harmoni-3 trial, and the Chinese, Akeso-sponsored Harmoni-2 study (testing monotherapy in PD-L1-expressing NSCLC) impressed at last year's World Lung conference – with caveats. Akeso has separately initiated a pivotal trial testing ivonescimab plus chemo in triple-negative breast cancer, but Summit isn't active here. VEGF x PD-(L)1 bispecifics continue to generate deal interest, and Innolake Biopharm's ILB-2201 has emerged as a recent entrant. Instil Bio, a separate player that licensed IMM2510/SYN-2510 from ImmuneOnco, this week said it was hoping to take this project's chemo combo into a first-line NSCLC study this year. This will be driven by ImmuneOnco's recently initiated Chinese phase 1/2 study, which includes front-line patients and is expected to yield data "as soon as the second half of 2025".

 

Pivotal trials of ivonescimab in NSCLC


 

Summit

Akeso

1st-line all-comersHarmoni-3*AK112-306
Chemo combo, vs Keytruda + chemoChemo combo, vs Tevimbra + chemo
1st-line PD-L1≥1%(none)Harmoni-2
MonRx, vs Keytruda
1st-line PD-L1>50%Harmoni-7(none)
MonoRx, vs Keytruda
2nd-line non-sq, EGFRm (post EGFRi)HarmoniHarmoni-A
Chemo combo, vs chemo

Note: *Harmoni-3 inclusion criteria as stated on clinicaltrials.gov mandate "TPS with PD-L1 expression prior to randomisation", but Summit states that this is an all-comers study. Source: OncologyPipeline.